BioRestorative Therapies ( NASDAQ: BRTX ) has regained compliance with Nasdaq listing rule in connection with the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, with the SEC . For Q1, 2024, the Co. had a loss from operations of $4.
1M, a 29% improvement from the $5.8M loss from operations for the comparable period of 2023. The Co.
’s net loss was $2.2M, or $0.33/share, compared to a net loss of $7.
2M, or $1.93/share, for the comparable period in 2023. Cash used in operating activities was $2.
3M, compared to $2.4M in Q1-2023. The Co.
ended Q1 in a strong financial position, with cash, cash equivalents, and investments held in marketable securities of $16.4M as of March 31, 2024. More on BioRestorative Therapies BioRestorative Therapies, Inc.
(BRTX) Q1 2024 Earnings Call Transcript BioRestorative spikes on talks for a potential licensing pact BioRestorative Therapies receives Nasdaq notice of non-compliance Seeking Alpha’s Quant Rating on BioRestorative Therapies Historical earnings data for BioRestorative Therapies.
